{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:27:53Z","timestamp":1792106873672,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1136\/ard.2009.122259","type":"journal-article","created":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T22:22:01Z","timestamp":1275690121000},"page":"1441-1447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":382,"title":["Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis"],"prefix":"10.1016","volume":"69","author":[{"given":"Monika","family":"Schoels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Funovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1136\/ard.2009.122259_bib1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4419-0298-6_4","article-title":"The enthesis organ concept and its relevance to the spondyloarthropathies","volume":"649","author":"Benjamin","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2009.122259_bib3","first-page":"627","article-title":"Psoriatic arthritis","volume":"21","author":"Wright","year":"1971","journal-title":"Bull Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology (Basel)"},{"key":"10.1136\/ard.2009.122259_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.24280","article-title":"Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis","volume":"61","author":"Fern\u00e1ndez-Sueiro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.122259_bib6","first-page":"1159","article-title":"Outcome measures in psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2009.122259_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1136\/ard.2009.122259_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1136\/ard.2009.122259_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11926-006-0062-y","article-title":"Dactylitis: pathogenesis and clinical considerations","volume":"8","author":"Healy","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2009.122259_bib10","first-page":"575","article-title":"Interpretation and power of a pooled index","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2009.122259_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.122259_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.122259_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.122259_bib15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.122259_bib16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib17","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/ard.2006.051706","article-title":"Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors","volume":"65","author":"Fransen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard.2009.117945","article-title":"Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis","volume":"69","author":"Nell-Duxneuner","year":"2010","journal-title":"Ann Rheum Dis 2009"},{"key":"10.1136\/ard.2009.122259_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/rheumatology\/39.2.148","article-title":"Development of a disease activity index for the assessment of reactive arthritis (DAREA)","volume":"39","author":"Eberl","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2009.122259_bib20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2009.122259_bib21","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2009.122259_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib23","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"5 Suppl 39","key":"10.1136\/ard.2009.122259_bib24","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2009.122259_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.122259_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.22489","article-title":"Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options","volume":"56","author":"Turkiewicz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.122259_bib27","first-page":"758","article-title":"A methodologic framework for developing and selecting endpoints in clinical trials","volume":"9","author":"Tugwell","year":"1982","journal-title":"J Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724193855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724193855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2009.122259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T20:11:05Z","timestamp":1737231065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724193855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0003496724193855"],"URL":"https:\/\/doi.org\/10.1136\/ard.2009.122259","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2009.122259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}